22 Results for "

PD-L1/L2

" in MedChemExpress (MCE) Product Catalog:
Products (22)

22 Results for "PD-L1/L2" in MCE Product Catalog:

37
37 Publications Verification
Cat. No.: HY-P9902A
Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 [2].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99052
CAS No.: 1858168-59-8
Synonyms: BGB-A317
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma [1] [2] .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99048
CAS No.: 2072873-06-2
Synonyms: IBI308

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer [1] [2] .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1812
CAS No.: 1353563-85-5
Synonyms: NP-12
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) [1].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1812A
Synonyms: NP-12 TFA
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

AUNP-12 TFA (NP-12 TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 TFA exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs) [1].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-101093
CAS No.: 1673534-76-3
Purity:  99.39%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes [1] [2].
loading...
    loading...
Cat. No.: HY-P990788

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse PD-1. Anti-Mouse PD-1 Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer [1] [2] .
loading...
    loading...
Cat. No.: HY-P99345
CAS No.: 2022215-59-2
Synonyms: TSR-042; ANB-011; WBP-285

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively [1].
loading...
    loading...
Cat. No.: HY-P99499
CAS No.: 2050478-92-5
Synonyms: JNJ 63723283; JNJ 3283

Research Areas:  

Cancer

Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo [1].
loading...
    loading...
Cat. No.: HY-P9996
CAS No.: 2445259-99-2
Synonyms: LY3434172; IBI-318

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC50 of 2.27 nM and an EC50 of 0.080 nM against human PD-1, as well as an IC50 of 0.75 nM and an EC50 of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer [1] [2].
loading...
    loading...
Cat. No.: HY-P99641
CAS No.: 1808081-43-7

Research Areas:  

Cancer

Gilvetmab is a canine-derived anti-cPD-1 monoclonal antibody, as well as an immune activator/antitumor agent. Gilvetmab binds to canine PD-1, blocks the interaction of PD-1/PD-L1/L2, prevents immunosuppression, reactivates antitumor responses, induces tumor regression or disease stabilization, and may also trigger pseudoprogression. Gilvetmab can be used in research related to malignant melanoma and mast cell tumors [1] [2] .
loading...
    loading...
Cat. No.: HY-P99884
CAS No.: 2206792-50-7
Synonyms: PF-06801591

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma [1] [2].
loading...
    loading...
Cat. No.: HY-P99573
CAS No.: 2245725-04-4
Synonyms: MGD-013

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity [1] [2] .
loading...
    loading...
Cat. No.: HY-P99610
CAS No.: 2249882-54-8
Synonyms: BI-754091

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo [1].
loading...
    loading...
Cat. No.: HY-P9972
CAS No.: 1935694-88-4
Synonyms: PDR001

Target:  

PD-1/PD-L1 IFNAR

Research Areas:  

Cancer

Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) [1] [2].
loading...
    loading...
Cat. No.: HY-P99109
CAS No.: 2259860-24-5
Synonyms: GLS-010; AB-122; WBP-3055

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma [1] [2].
loading...
    loading...
Cat. No.: HY-P990170

Research Areas:  

Inflammation/Immunology

Anti-Mouse PD-L2/B7-DC Antibody (TY25) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse PD-L2/B7-DC. Anti-Mouse PD-L2/B7-DC Antibody (TY25) blocks PD-L2 binding to PD-1 and blocks PD-1 signaling. Anti-Mouse PD-L2/B7-DC Antibody (TY25) can be used for the researches of inflammation and immunology, such as conjunctivitis and transplantation [1] [2] .
loading...
    loading...
Cat. No.: HY-P99639
CAS No.: 2348469-43-0
Synonyms: Genolimzumab; APL-501; CBT-501; GB-226

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer [1].
loading...
    loading...
Cat. No.: HY-P99048A
Synonyms: IBI308 (Anti-PD-1)

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer [1] [2] .
loading...
    loading...
Cat. No.: HY-P991353

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models [1].
loading...
    loading...